Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Sol…
Medical - Diagnostics & Research
US, Waltham [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -21.26 | 98.64 | 125.27 | |
| Graham Fair Price | -9.75 | 96.54 | 106.97 | |
| PEG | 60.37 | -2.41 | -6.08 | |
| Price/Book | 10.95 | 4.88 | 4.40 | |
| Price/Cash Flow | 296.71 | 245.60 | 61.91 | |
| Prices/Earnings | 32.66 | 41.80 | 31.51 | |
| Price/Sales | 13.74 | 21.46 | 18.87 | |
| Price/FCF | 296.71 | 245.60 | 61.91 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -1.30 | 0.41 | 0.41 | |
| Operating Margin | -2.38 | 0.17 | 0.17 | |
| ROA | -17.16 | 0.01 | 0.02 | |
| ROE | 0.03 | 0.03 | -16.37 | |
| ROIC | 0.02 | 0.02 | -28.60 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.02 | -0.01 | 90.26 | |
| Dividends QOQ | < 0.005 | < 0.005 | 17.39 | |
| EBIT QOQ | < 0.005 | -0.07 | -1247.23 | |
| EPS QOQ | -0.05 | -0.17 | -234.73 | |
| FCF QOQ | 0.59 | -0.73 | 22.55 | |
| Revenue QOQ | 0.03 | -0.05 | 68.43 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 71.66 | 75.39 | 5.20 | |
| Days Sales Outstanding (DSO) | 67.97 | 81.37 | 19.72 | |
| Inventory Turnover | 1.26 | 1.19 | -4.94 | |
| Debt/Capitalization | 0.43 | 0.44 | 2.63 | |
| Quick Ratio | 1.16 | 1.19 | 2.46 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 120.73 | 119.15 | -1.31 | |
| Cash | 20.87 | 19.00 | -8.98 | |
| Capex | -1.05 | -0.91 | 13.20 | |
| Free Cash Flow | 8.57 | 2.37 | -72.40 | |
| Revenue | 28.13 | 27.08 | -3.73 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Weak